Japan's Nuclear Crisis Puts Small Radiation Drug Companies on the Radar (CBLI) (OSIS) (AOLS)
Tweet Send to a Friend
Get Alerts CBLI Hot Sheet
Up)
Trade CBLI Now!
An article in the New York Times Friday pointed out how the nuclear crisis in Japan has put into the spotlight some small biotechnology companies that are developing drugs that treat radiation poisoning.
Companies mentioned in the article included Cleveland BioLabs, Inc. (Nasdaq: CBLI) and Osiris Therapeutics (Nasdaq: OSIS).
Cleveland BioLabs is developing a drug that fools the body into believing there has been a "massive salmonella infection", which then triggers a response that produces Neupogen to help restore the immune system and gastrointestinal tract.
The Defense Department awarded Osiris Therapeutics a $224 million contract to develop a therapy using stem cells to help repair gastrointestinal injuries.
Another company mentioned in the article was micro-cap Aeolus Pharmaceuticals Inc. (OTCBB: AOLS) which has recently seen 5.6 million shares trade hands on a single day, or more than 1,000 times normal.
The CEO of the company was quoted as saying "it was crazy, just crazy." The article notes that Aeolus has a federal contract worth up to $118 million to develop drug to protect the lungs from radiation.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Companies mentioned in the article included Cleveland BioLabs, Inc. (Nasdaq: CBLI) and Osiris Therapeutics (Nasdaq: OSIS).
Cleveland BioLabs is developing a drug that fools the body into believing there has been a "massive salmonella infection", which then triggers a response that produces Neupogen to help restore the immune system and gastrointestinal tract.
The Defense Department awarded Osiris Therapeutics a $224 million contract to develop a therapy using stem cells to help repair gastrointestinal injuries.
Another company mentioned in the article was micro-cap Aeolus Pharmaceuticals Inc. (OTCBB: AOLS) which has recently seen 5.6 million shares trade hands on a single day, or more than 1,000 times normal.
The CEO of the company was quoted as saying "it was crazy, just crazy." The article notes that Aeolus has a federal contract worth up to $118 million to develop drug to protect the lungs from radiation.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Will Erickson Air-Crane (EAC) Stock Crash and Burn?
- Notable Winners and Losers from Q1 Earnings Season: (YRCW) (TSLA) (AVEO) (CRMB)
- 3D Systems (DDD) Execs Unload 1.28M Shares
Create E-mail Alert Related Categories
Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
